GoodRx 2026 Guidance Signals Material Reset, Morgan Stanley Says

MT Newswires Live02-28

GoodRx (GDRX) faces a material reset after issuing 2026 guidance that came in meaningfully below street expectations, reflecting continued weakness in its core prescriptions marketplace that more than offsets strength in Pharma Direct, Morgan Stanley said in a Friday note.

Management guided 2026 revenue to $750 million to $780 million and adjusted EBITDA above $230 million, both below street estimates. The outlook reflects a shift toward Pharma Direct as a key growth driver. It also incorporates heavier investment in Pharma Direct and subscription offerings, alongside ongoing headwinds in prescription transactions.

Morgan Stanley lowered its 2026 EBITDA estimate by nearly 20%. The investment firm said roughly half of the expected 2026 EBITDA step-down reflects the rollover of 2025 contributions, including impacts tied to Rite Aid and other partner programs that ended mid-year.

The remaining half stems from weaker core prescription economics and incremental investments in Pharma Direct and condition-specific subscriptions. Low visibility and disappointing growth keep the firm on the sidelines, according to the note.

Morgan Stanley lowered its price target to $3 from $4, with an equal-weight rating.

Shares of GoodRx were down more than 3% in recent trading.

Price: 1.93, Change: -0.07, Percent Change: -3.27

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614868218?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-28 00:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614868218","market":"fut","top_or_hot":-1,"title":"GoodRx 2026 Guidance Signals Material Reset, Morgan Stanley Says","media":"MT Newswires Live","content":"<html><body><p> GoodRx (GDRX) faces a material reset after issuing 2026 guidance that came in meaningfully below street expectations, reflecting continued weakness in its core prescriptions marketplace that more than offsets strength in Pharma Direct, Morgan Stanley said in a Friday note.</p><p>Management guided 2026 revenue to $750 million to $780 million and adjusted EBITDA above $230 million, both below street estimates. The outlook reflects a shift toward Pharma Direct as a key growth driver. It also incorporates heavier investment in Pharma Direct and subscription offerings, alongside ongoing headwinds in prescription transactions.</p><p>Morgan Stanley lowered its 2026 EBITDA estimate by nearly 20%. The investment firm said roughly half of the expected 2026 EBITDA step-down reflects the rollover of 2025 contributions, including impacts tied to <a href=\"https://laohu8.com/S/RADCQ\">Rite Aid</a> and other partner programs that ended mid-year.</p><p>The remaining half stems from weaker core prescription economics and incremental investments in Pharma Direct and condition-specific subscriptions. Low visibility and disappointing growth keep the firm on the sidelines, according to the note.</p><p>Morgan Stanley lowered its price target to $3 from $4, with an equal-weight rating.</p><p>Shares of GoodRx were down more than 3% in recent trading.</p><p>Price: 1.93, Change: -0.07, Percent Change: -3.27</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GoodRx 2026 Guidance Signals Material Reset, Morgan Stanley Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoodRx 2026 Guidance Signals Material Reset, Morgan Stanley Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-28 00:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> GoodRx (GDRX) faces a material reset after issuing 2026 guidance that came in meaningfully below street expectations, reflecting continued weakness in its core prescriptions marketplace that more than offsets strength in Pharma Direct, Morgan Stanley said in a Friday note.</p><p>Management guided 2026 revenue to $750 million to $780 million and adjusted EBITDA above $230 million, both below street estimates. The outlook reflects a shift toward Pharma Direct as a key growth driver. It also incorporates heavier investment in Pharma Direct and subscription offerings, alongside ongoing headwinds in prescription transactions.</p><p>Morgan Stanley lowered its 2026 EBITDA estimate by nearly 20%. The investment firm said roughly half of the expected 2026 EBITDA step-down reflects the rollover of 2025 contributions, including impacts tied to <a href=\"https://laohu8.com/S/RADCQ\">Rite Aid</a> and other partner programs that ended mid-year.</p><p>The remaining half stems from weaker core prescription economics and incremental investments in Pharma Direct and condition-specific subscriptions. Low visibility and disappointing growth keep the firm on the sidelines, according to the note.</p><p>Morgan Stanley lowered its price target to $3 from $4, with an equal-weight rating.</p><p>Shares of GoodRx were down more than 3% in recent trading.</p><p>Price: 1.93, Change: -0.07, Percent Change: -3.27</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0971096721.USD","symbol_name":"富达环球金融服务 A","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2614868218","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614868218","pubTimestamp":1772208264,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"GoodRx (GDRX) faces a material reset after issuing 2026 guidance that came in meaningfully below street expectations, reflecting continued weakness in its core prescriptions marketplace that more than","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0971096721.USD":"富达环球金融服务 A","BK4581":"高盛持仓","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU0557290698.USD":"施罗德环球可持续增长基金","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","BK4585":"ETF&股票定投概念","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","BK4127":"投资银行业与经纪业","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1732800096.USD":"摩根大通环球收益基金A (irc)","GDRX":"GoodRx Holdings, Inc.","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU1548497426.USD":"安联环球人工智能AT Acc","BK4516":"特朗普概念","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","BK4167":"医疗保健技术","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","BK4504":"桥水持仓","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4588":"碎股","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","MS":"摩根士丹利","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC"},"translate_title":"摩根士丹利表示，GoodRx 2026指引标志着材料重置","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GDRX":1,"MS":0.9},"content_text":"GoodRx (GDRX) faces a material reset after issuing 2026 guidance that came in meaningfully below street expectations, reflecting continued weakness in its core prescriptions marketplace that more than offsets strength in Pharma Direct, Morgan Stanley said in a Friday note.Management guided 2026 revenue to $750 million to $780 million and adjusted EBITDA above $230 million, both below street estimates. The outlook reflects a shift toward Pharma Direct as a key growth driver. It also incorporates heavier investment in Pharma Direct and subscription offerings, alongside ongoing headwinds in prescription transactions.Morgan Stanley lowered its 2026 EBITDA estimate by nearly 20%. The investment firm said roughly half of the expected 2026 EBITDA step-down reflects the rollover of 2025 contributions, including impacts tied to Rite Aid and other partner programs that ended mid-year.The remaining half stems from weaker core prescription economics and incremental investments in Pharma Direct and condition-specific subscriptions. Low visibility and disappointing growth keep the firm on the sidelines, according to the note.Morgan Stanley lowered its price target to $3 from $4, with an equal-weight rating.Shares of GoodRx were down more than 3% in recent trading.Price: 1.93, Change: -0.07, Percent Change: -3.27","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614868218","isCrawlerRequest":true}